These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18070457)

  • 21. Mouse models reveal why Alzheimer's treatment fails.
    Niemeyer JE
    Lab Anim (NY); 2016 Apr; 45(4):125. PubMed ID: 27003340
    [No Abstract]   [Full Text] [Related]  

  • 22. Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease.
    Lannfelt L; Pettersson FE; Nilsson LN
    Nutr Rev; 2010 Dec; 68 Suppl 2():S128-34. PubMed ID: 21091946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for Alzheimer's disease.
    Steinitz M
    Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
    Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genentech's Alzheimer's antibody trial to study disease prevention.
    Garber K
    Nat Biotechnol; 2012 Aug; 30(8):731-2. PubMed ID: 22871696
    [No Abstract]   [Full Text] [Related]  

  • 26. Challenges of targeting A beta fibrillogenesis and other protein folding disorders.
    LeVine H
    Amyloid; 2003 Sep; 10(3):133-5. PubMed ID: 14640025
    [No Abstract]   [Full Text] [Related]  

  • 27. Gantenerumab for the treatment of Alzheimer's disease.
    Delrieu J; Ousset PJ; Vellas B
    Expert Opin Biol Ther; 2012 Aug; 12(8):1077-86. PubMed ID: 22583155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
    Schenk DB; Seubert P; Grundman M; Black R
    Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration.
    Takata K; Hirata-Fukae C; Becker AG; Chishiro S; Gray AJ; Nishitomi K; Franz AH; Sakaguchi G; Kato A; Mattson MP; Laferla FM; Aisen PS; Kitamura Y; Matsuoka Y
    Eur J Neurosci; 2007 Nov; 26(9):2458-68. PubMed ID: 17970733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of beta-amyloid peptide in pathogenesis and immunotherapy of Alzheimer's diseases].
    Yu SN; Liu LY; Liang P
    Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):113-4. PubMed ID: 15842811
    [No Abstract]   [Full Text] [Related]  

  • 31. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease.
    Banks WA; Terrell B; Farr SA; Robinson SM; Nonaka N; Morley JE
    Peptides; 2002 Dec; 23(12):2223-6. PubMed ID: 12535702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Alzheimer's disease: the beginning of a new era.
    Schenk D
    Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
    Solomon B
    Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of intraventricularly administered antiamyloid-beta peptide (Abeta) antibody in the mouse brain.
    Chauhan NB; Siegel GJ; Lichtor T
    J Neurosci Res; 2001 Oct; 66(2):231-5. PubMed ID: 11592118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease.
    Rotman M; Welling MM; Bunschoten A; de Backer ME; Rip J; Nabuurs RJ; Gaillard PJ; van Buchem MA; van der Maarel SM; van der Weerd L
    J Control Release; 2015 Apr; 203():40-50. PubMed ID: 25668771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.
    Selkoe DJ; Schenk D
    Annu Rev Pharmacol Toxicol; 2003; 43():545-84. PubMed ID: 12415125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.
    Counts SE; Lahiri DK
    Curr Alzheimer Res; 2014; 11(7):623-5. PubMed ID: 25156573
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-amyloid antibody drugs in clinical testing for Alzheimer's disease.
    Bednar MM
    IDrugs; 2009 Sep; 12(9):566-75. PubMed ID: 19697276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bapineuzumab in Alzheimer's disease: where now?
    Wilcock GK
    Lancet Neurol; 2010 Feb; 9(2):134-6. PubMed ID: 20129159
    [No Abstract]   [Full Text] [Related]  

  • 40. [Adaptive immunity to Aβ amyloid peptide in Alzheimer's disease: lessons and perspectives].
    Dorothée G; Aucouturier P
    Med Sci (Paris); 2011 Nov; 27(11):938-40. PubMed ID: 22130019
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.